MetaCap

NewAmsterdam Pharma N.V. (NAMS) vs Arcus Biosciences (RCUS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arcus Biosciences (RCUS) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, losing 29.2% versus a loss of 51.9%. Over five years, NAMS leads with a +88.0% price change compared with -66.3% for RCUS. Arcus Biosciences is the larger company by market cap ($2.25 billion vs $2.21 billion), about 1.0 times the size.

Arcus Biosciences converts more of its revenue into profit, with a net margin of -142.9% versus -905.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NAMS-51.89%RCUS-29.16%
+48%-4%-57%
Nov 21, 20251 yearNov 20, 2026
NAMS+87.47%RCUS-67.15%
+341%+118%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NAMS versus RCUS key metrics
MetricNAMSRCUS
Share price$18.41$15.62
Market cap$2.21B$2.25B
1-day change-5.64%-1.01%
YTD return-47.52%-34.45%
1-year return-51.89%-29.16%
5-year return+88.05%-66.31%
EPS (TTM)$-1.69$-3.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$22.50M$247.00M
Revenue growth (YoY)-50.61%-4.26%
Net income (latest FY)$-203.82M$-353.00M
Operating margin-1002.90%-156.28%
Net margin-905.74%-142.91%
52-week high$42.21$31.74
52-week low$17.90$15.56
Distance from 52-week high-56.38%-50.78%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+174.85%+162.48%
Average volume1.66M1.85M
Shares outstanding119.93M143.99M
Employees100601
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RCUS has outperformed NAMS by 22.7 percentage points over the past year.
  • Arcus Biosciences is more profitable, keeping -142.9 cents of every revenue dollar as net income versus -905.7 cents for NewAmsterdam Pharma N.V..
  • Arcus Biosciences grew revenue faster in its latest fiscal year (-4.26% vs -50.61%).

About NewAmsterdam Pharma N.V.

NAMS stock →

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Arcus Biosciences

RCUS stock →

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees

NAMS vs RCUS FAQ

Which is bigger, NewAmsterdam Pharma N.V. or Arcus Biosciences?

Arcus Biosciences (RCUS) is larger, with a market capitalization of $2.25B compared with $2.21B for NewAmsterdam Pharma N.V. (NAMS).

Which stock has performed better over the past year, NAMS or RCUS?

RCUS returned -29.16% over the past 12 months, compared with -51.89% for NAMS (price return, excluding dividends). Past performance does not predict future results.

Are NewAmsterdam Pharma N.V. and Arcus Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons